Protagonist Q2 net loss $38.5M; JNJ-2113 advances to Phase 3 in psoriasis

Protagonist Therapeutics, Inc

2023-Q2 EPS reported -$1.34

Net loss of $38.5M ($0.68/share) in Q2 2023 vs $41M loss in Q2 2022; cash $313.4M at June 30.
JNJ-2113 Phase 2b FRONTIER 1 met all endpoints; 78.6% PASI 75 at 100mg BID; moving to Phase 3 psoriasis and Phase 2b UC.
Rusfertide Phase 2 REVIVE positive results presented at EHA2023; Phase 3 VERIFY enrollment continues targeting Q1 2024 completion.
Completed $115M equity financing in April 2023.
License revenue $0 vs $0.9M in Q2 2022 as prior period included $25M milestone.

item 2.02 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.9

Protagonist Therapeutics, Inc reported the second quarter ended June 30, 2023 results: revenue zero, net income Net loss was $38.5 million, or $0.68 per share, for the three months ended June 30, 2023, EPS $0.68 per share.

Period: the second quarter ended June 30, 2023
Revenue: zero
Net income: Net loss was $38.5 million, or $0.68 per share, for the three months ended June 30, 2023
EPS: $0.68 per share
Result: reported results

Exact text from the filing

On August 3, 2023, Protagonist Therapeutics, Inc. reported its financial results for the second quarter ended June 30, 2023.

View on SEC.gov

Browse all earnings releases →

Protagonist Therapeutics, Inc filing history →

Source: SEC EDGAR

accession 0001104659-23-087269

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.